A small early dataset for experimental cell therapy in uveal melanoma reported tumor shrinkage in all treated patients across a Phase 1 experience involving 16 individuals. The preliminary findings, presented at major oncology meetings, are being framed internally as a potential route to extend immune-oncology strategies beyond uveal melanoma to other hard-to-treat solid tumors such as pancreatic and ovarian cancers.